6 January 2023 - - US-based biotechnology company Asher Biotherapeutics, Inc has appointed Elaine Sun to its board of directors, the company said.

Sun currently serves as chief operating officer and chief financial officer of Mammoth Biosciences, Inc. (Mammoth Biosciences).

Sun has more than twenty-five years of experience in life sciences. Prior to her role as chief operating officer and chief financial officer at Mammoth Biosciences, Sun served as senior vice president and chief financial officer at Halozyme Therapeutics, Inc. (Halozyme).

Prior to Halozyme, she served as chief financial officer and Chief Strategy officer at SutroVax, Inc. (now known as Vaxcyte, Inc.).

Over the course of these roles, Elaine provided leadership to rapidly growing organizations, and led a number of functions including finance, accounting, information technology, site operations, and commercial business units.

Previously, Sun served as Managing director and Head of West Coast Healthcare for Evercore Partners and Managing director at Merrill Lynch & Co., Inc.

During her career, she has led and played key roles in a broad range of transactions, including multiple mergers, acquisitions, and financings, valued in excess of USD 50bn.

Sun currently serves on the board of directors of Dynavax Technologies Corp. and previously served on the board of directors of Cirius Therapeutics.

She received her B.A. from Wellesley College and M.B.A from Harvard Business School.

Asher Bio is a biotechnology company developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infection and autoimmune disease.

Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco.